By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Metamark Genetics said yesterday that it has signed a research and licensing deal with Janssen Biotech on identifying and validating prognostic markers for cancer.

The firms intend to validate several of Metamark's Prognostic Determinants, which are genes that are believed to play a causal role in promoting tumor progression and metastases. Cambridge, Mass.-based Metamark makes MetamarkDx Prognostic Assays based on the Prognostic Determinants technology.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Ancient DNA indicates Stone Age, hunter-gather inhabitants of Britain imported wheat.

Joel Achenbach explores at National Geographic why people find science difficult to believe.

In Science this week: gene linked to expansion of the human neocortex, and more.

The National Institute of General Medical Sciences director says changes the agency made have allow it to boost success rates.